Clinical Trials Logo

Systemic Mastocytosis clinical trials

View clinical trials related to Systemic Mastocytosis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03214666 Terminated - Clinical trials for Acute Myelogenous Leukemia

GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies

Start date: January 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-center Phase I/II clinical trial of GTB-3550 (CD16/IL-15/CD33) tri-specific killer cell engager (TriKE®) for the treatment of CD33-expressing high risk myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis. The hypothesis is that GTB-3550 TriKE® will induce natural killer cell function by targeting malignant cells as well as CD33+ myeloid derived suppressor cells (MDSC) which contribute to tumor induced immunosuppression. Because CD16 is the most potent activating receptor on natural killer (NK) cells, this single agent may induce a targeted anti-CD33+ tumor response.

NCT ID: NCT02415608 Terminated - Mast Cell Leukemia Clinical Trials

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Start date: March 2015
Phase: Phase 2
Study type: Interventional

This phase 2 trial studies ibrutinib to see how well it works in treating patients with systemic (affecting the entire body) mastocytosis that has spread to other parts of the body and usually cannot be cured or controlled with treatment (advanced). Systemic mastocytosis is a disease in which too many mast cells (a type of immune system cell) are found throughout the body. Mast cells give off chemicals such as histamine that can cause flushing (a hot, red face), itching, abdominal cramps, muscle pain, nausea, vomiting, diarrhea, low blood pressure, and shock. Ibrutinib may stop the growth of mast cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00918931 Terminated - Leukemia Clinical Trials

Obatoclax for Systemic Mastocytosis

Start date: June 2009
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if obatoclax mesylate can help to control systemic mastocytosis. The safety of this drug will also be tested.